The Akt pathway: molecular targets for anti-cancer drug development - PubMed (original) (raw)
Review
The Akt pathway: molecular targets for anti-cancer drug development
Constantine S Mitsiades et al. Curr Cancer Drug Targets. 2004 May.
Abstract
The serine/threonine kinase Akt functions intracellularly as a cardinal nodal point for a constellation of converging upstream signaling pathways, which involve stimulation of receptor tyrosine kinases such as IGF-1R, HER2/Neu, VEGF-R, PDGF-R), and an assembly of membrane-localized complexes of receptor-PI-3K and activation of Akt through the second messenger PIP(3). The integration of these intracellular signals at the level of Akt and its kinase activity, regulates the phosphorylation of its several downstream effectors, such as NF-kappa B, mTOR, Forkhead, Bad, GSK-3 and MDM-2. These phosphorylation events in turn mediate the effects of Akt on cell growth, proliferation, protection from pro-apoptotic stimuli, and stimulation of neo-angiogenesis. Because Akt and its upstream regulators are deregulated in a wide range of solid tumors and hematologic malignancies, and in view of the aforementioned biologic sequelae of this pathway, the Akt pathway is considered a key determinant of biologic aggressiveness of these tumors, and a major potential target for novel anti-cancer therapies. This review focuses on ongoing translational efforts to therapeutically target Akt and its biologic sequelae, either at the level of Akt itself or at the levels of its upstream regulators and downstream effectors. Because Akt is also important for proliferative and anti-apoptotic signaling pathways critical for normal cells, particular emphasis is placed on the fine-tuning the targeting of individual components of this pathway to maximize the therapeutic index of anti-cancer strategies based on the PI-3K/Akt pathway.
Similar articles
- Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma.
Pene F, Claessens YE, Muller O, Viguié F, Mayeux P, Dreyfus F, Lacombe C, Bouscary D. Pene F, et al. Oncogene. 2002 Sep 26;21(43):6587-97. doi: 10.1038/sj.onc.1205923. Oncogene. 2002. PMID: 12242656 - Phosphatidylinositol 3-kinase (PI-3K)/Akt but not PI-3K/p70 S6 kinase signaling mediates IGF-1-promoted lens epithelial cell survival.
Chandrasekher G, Sailaja D. Chandrasekher G, et al. Invest Ophthalmol Vis Sci. 2004 Oct;45(10):3577-88. doi: 10.1167/iovs.04-0279. Invest Ophthalmol Vis Sci. 2004. PMID: 15452065 - The B cell antigen receptor activates the Akt (protein kinase B)/glycogen synthase kinase-3 signaling pathway via phosphatidylinositol 3-kinase.
Gold MR, Scheid MP, Santos L, Dang-Lawson M, Roth RA, Matsuuchi L, Duronio V, Krebs DL. Gold MR, et al. J Immunol. 1999 Aug 15;163(4):1894-905. J Immunol. 1999. PMID: 10438924 - Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy.
Chang F, Lee JT, Navolanic PM, Steelman LS, Shelton JG, Blalock WL, Franklin RA, McCubrey JA. Chang F, et al. Leukemia. 2003 Mar;17(3):590-603. doi: 10.1038/sj.leu.2402824. Leukemia. 2003. PMID: 12646949 Review. - The protein kinase B/Akt signalling pathway in human malignancy.
Nicholson KM, Anderson NG. Nicholson KM, et al. Cell Signal. 2002 May;14(5):381-95. doi: 10.1016/s0898-6568(01)00271-6. Cell Signal. 2002. PMID: 11882383 Review.
Cited by
- The Role of Long Noncoding RNAs (lncRNAs) in Esophageal Cancer Therapy Resistance and Metastasis.
Weng ZP, Hsu SK, Wang HD, Chen KJ, Lee PY, Chiu CC, Cheng KC. Weng ZP, et al. Biomedicines. 2024 Mar 15;12(3):660. doi: 10.3390/biomedicines12030660. Biomedicines. 2024. PMID: 38540273 Free PMC article. Review. - Discovering Tuberosin and Villosol as Potent and Selective Inhibitors of AKT1 for Therapeutic Targeting of Oral Squamous Cell Carcinoma.
Adnan M, Jairajpuri DS, Chaddha M, Khan MS, Yadav DK, Mohammad T, Elasbali AM, Abu Al-Soud W, Hussain Alharethi S, Hassan MI. Adnan M, et al. J Pers Med. 2022 Jun 30;12(7):1083. doi: 10.3390/jpm12071083. J Pers Med. 2022. PMID: 35887580 Free PMC article. - Therapeutic Effect of Catgut Implantation at Acupoint in a Mouse Model of Hepatocellular Carcinoma by Suppressing Immune Escape.
Xu SH, Luo HX, Huang BJ, Yu L, Luo SJ, Hu H, Li Y, Lin XT, Cao ZR, Deng YJ, Zhang SJ. Xu SH, et al. Evid Based Complement Alternat Med. 2022 Feb 8;2022:5572869. doi: 10.1155/2022/5572869. eCollection 2022. Evid Based Complement Alternat Med. 2022. PMID: 35178106 Free PMC article. - Tumor Microenvironment Features and Chemoresistance in Pancreatic Ductal Adenocarcinoma: Insights into Targeting Physicochemical Barriers and Metabolism as Therapeutic Approaches.
Carvalho TMA, Di Molfetta D, Greco MR, Koltai T, Alfarouk KO, Reshkin SJ, Cardone RA. Carvalho TMA, et al. Cancers (Basel). 2021 Dec 6;13(23):6135. doi: 10.3390/cancers13236135. Cancers (Basel). 2021. PMID: 34885243 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous